



Highly effective and stable bispecific diabody for cancer immunotherapy


① Summary



② anti-tumor effect of humanized Ex3 (in vivo)




③ high activation of Ex3




④ Effect of IgG type Ex3 & LH type Ex3 (in vitro)

human bile duct carcinoma (TFK-1) : activated T cell = 1 : 5



⑤ Effect of amino acid mutant of Ex3 (in vitro)



⑥ comparison of anti-tumor effect

1. cetuximab (25µg/kg) < Ex3 (0.1µg/kg)
2. Ex3 < fc fused Ex3
3. HL type Ex3 < LH type Ex3
4. Ex3 (HL) < fc fused Ex3 (HL) < Ex3 (LH) < fc fused Ex3 (LH)
5. amino acid mutant of Ex3 series has higher anti-tumor effect than original Ex3 series

Patent Information

Patent App. No. : JPB3803790, JPB5082104,

JPB5725508, JPB5818003

Inventor : Dr. KUMAGAI Izumi et. al

Contact

Tohoku Techno Arch Co., LTD

TEL:+81-22-222-3049, FAX:+81-22-222-3419

[Click](#) to contact